We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+19.28%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$8.67B
AUM Growth
+$1.11B
Cap. Flow
+$178M
Cap. Flow %
2.05%
Top 10 Hldgs %
55.18%
Holding
87
New
9
Increased
9
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
BCAX
Bicara Therapeutics
BCAX
+$177M
2
ARTV
Artiva Biotherapeutics
ARTV
+$114M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$51.1M
4
BIOA
BioAge Labs
BIOA
+$44.3M
5
PCVX icon
Vaxcyte
PCVX
+$43.7M

Top Sells

Rank Stock Value
1
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$88.9M
2
VRNA
Verona Pharma
VRNA
+$64.6M
3
GERN icon
Geron
GERN
+$63.3M
4
ASND icon
Ascendis Pharma A/S
ASND
+$53.7M
5
URGN icon
UroGen Pharma
URGN
+$51.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Financials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRZN icon
76
Surrozen
SRZN
$255M
$3.39M 0.04%
282,580
– –
MGX icon
77
Metagenomi Therapeutics
MGX
$45.9M
$2.83M 0.03%
1,305,239
-172,510
-12% -$598K
NAMSW icon
78
NewAmsterdam Pharma Warrant
NAMSW
$73.6M
$2.33M 0.03%
333,333
– –
ANTX icon
79
AN2 Therapeutics
ANTX
$210M
$2.14M 0.02%
1,999,997
-3,551,298
-64% -$6.16M
RGLS
80
DELISTED
Regulus Therapeutics
RGLS
$1.2M 0.01%
766,834
-5,483,166
-88% -$9.07M
SCLX icon
81
Scilex Holding
SCLX
$45.9M
$241K ﹤0.01%
7,462
– –
HELP
82
Cybin Inc
HELP
$653M
– –
-1,158,012
Closed -$11.9M
MGNX icon
83
MacroGenics
MGNX
$248M
– –
-2,082,021
Closed -$8.85M
NRIX icon
84
Nurix Therapeutics
NRIX
$2.61B
– –
-650,000
Closed -$13.6M
UNCY icon
85
Unicycive Therapeutics
UNCY
$143M
– –
-263,220
Closed -$1.32M
URGN icon
86
UroGen Pharma
URGN
$2.26B
– –
-3,083,430
Closed -$51.7M
LBPH
87
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
– –
-3,289,119
Closed -$88.9M
1 2 3
4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, RA Capital Management held 87 positions worth $8.67B, up 15% from $7.56B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RA Capital Management's Q3 2024 filing shows 9 new, 9 increased, 14 reduced and 6 closed positions. Its largest new stake was Bicara Therapeutics: 6,955,993 shares worth $177M. The largest sale was Longboard Pharmaceuticals, Inc. Common Stock, an estimated $88.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q3 2024 buy was Bicara Therapeutics: 6,955,993 shares worth $177M.
  • RA Capital Management added most to Vaxcyte in Q3 2024, an estimated $43.7M increase.
  • RA Capital Management's biggest Q3 2024 reduction was Verona Pharma, cutting an estimated $64.6M.
  • RA Capital Management fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q3 2024, selling an estimated $88.9M.
  • RA Capital Management's ten largest holdings make up 55% of its $8.67B portfolio in Q3 2024.
  • RA Capital Management opened 9 new positions and closed 6 in Q3 2024.
  • RA Capital Management's portfolio value rose 15% quarter-over-quarter to $8.67B.

Based on RA Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.